Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G01 Eye Drops in Optic Nerve Injury Associated With Open-Angle Glaucoma
NCT07777861Phase 2Recruiting
- Sponsor
- Qingdao Wanming Bio-Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of G01 Eye Drops in Optic neuropathies, primary open-angle glaucoma (POAG), sponsored by Qingdao Wanming Bio-Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
G01 Eye Drops
03
Conditions
Optic neuropathiesprimary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT07777861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07777861.